Publication at Faculty of Medicine in Pilsen, Faculty of Medicine in Hradec Králové |
2016
Abstract
Severe refractory asthma remains persistent clinical challenge, despite even high dose antiinflammatory and bronchodilation therapy is impossible to gain asthma control. Currently a new antiinflammatory therapy by mepolizumab (anti-IL-5) for endotype of severe eosinophillic refractory asthma is available for routine clinical use.
This paper summarize current published clinical experiences of mepolizumab therapy for severe asthma.